Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma

Journal of Translational Medicine

Research

Rui Mao¹  Da Liu¹  Fan Yang²  Tongtong Zhang³ 

[1] Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China;Emergency Department, Peking University Third Hospital, Peking University School of Medicine, 100083, Beijing, China;The Center of Gastrointestinal and Minimally Invasive Surgery, The Third People’s Hospital of Chengdu, 610031, Chengdu, China;Medical Research Center, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, 610031, Chengdu, Sichuan, China;

关键词: Cutaneous melanoma;    Cuproptosis-related genes;    Immunotherapy;    Prognosis;    Nomogram;   

DOI  :  10.1186/s12967-023-03891-4

 received in 2022-11-30, accepted in 2023-01-16,  发布年份 2023

来源: Springer

【 摘 要 】

Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. Cuproptosis is a newly discovered mode of cell death related to tumorigenesis. Exploring the relationship between the mode of cuproptosis and the effect of immunotherapy on CM could better guide clinical management. We clustered all patients with CM in the Cancer Genome Atlas (TCGA) database based on cuproptosis-related genes (CRGs). Prognosis, immunotherapeutic effect, tumor microenvironment score, expression of CD274, CTLA4, and PDCD1, and abundance of CD8 + T infiltration in group A were higher than in group B. Using a combination of LASSO and COX regression analysis, we identified 10 molecules significant to prognosis from differentially expressed genes between the two groups and constructed a cuproptosis-related scoring system (CRSS). Compared with the American Joint Committee on Cancer (AJCC) staging system, CRSS more accurately stratified CM patient risk and guided immunotherapy. CRSS successfully stratified risk and predicted the effect of immunotherapy in 869 patients with eight CM immunotherapy datasets and multiple other tumor immunotherapy cohorts. The nomogram model, which combined AJCC stage and CRSS, greatly improved the ability and accuracy of prognosis prediction. In general, our cuproptosis-related scoring system and nomogram model accurately stratified risk in CM patients and effectively predicted prognosis and the effect of immunotherapy in CM patients.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq643.gif

41116_2022_35_Article_IEq641.gif

41116_2022_35_Article_IEq639.gif

41116_2022_35_Article_IEq579.gif

41116_2022_35_Article_IEq569.gif

41116_2022_35_Article_IEq550.gif

41116_2022_35_Article_IEq517.gif

41116_2022_35_Article_IEq509.gif

41116_2022_35_Article_IEq495.gif

41116_2022_35_Article_IEq485.gif

Fig. 12